Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia
Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia have?
Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia has 14 citations in the OpenAlex counts ScholarIQ stores.
When was Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia published?
Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia has 2019 year in the ScholarIQ index.
What is the open-access status of Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia?
Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia has gold oa status in the ScholarIQ index.
What is the DOI of Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia?
The DOI for Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia is on the source record.
What is the PMID of Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia?
The PMID for Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia is on the source record.
What is the OpenAlex record for Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia?
The OpenAlex for Romidepsin enhances the efficacy of cytarabine <i>in vivo</i>, revealing histone deacetylase inhibition as a promising therapeutic strategy for <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia is on the source record.